The Enterprise Value as of December 2025 (TTM) for Lexicon Pharmaceuticals, Inc. (LXRX) is 556.11M

According to Lexicon Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 556.11M. This represents a change of 44.95% compared to the average of 383.65M of the last 4 quarters.

Lexicon Pharmaceuticals, Inc. (LXRX) Historical Enterprise Value (quarterly & annually)

How has LXRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Lexicon Pharmaceuticals, Inc. over the last ten years is 636.94M. The current 556.11M Enterprise Value has changed 8.63% with respect to the historical average. Over the past ten years (40 quarters), LXRX's Enterprise Value was at its highest in in the June 2017 quarter at 1.80B. The Enterprise Value was at its lowest in in the September 2020 quarter at 123.15M.

Lexicon Pharmaceuticals, Inc. (LXRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Lexicon Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lexicon Pharmaceuticals, Inc. (LXRX) Average Enterprise Value

How has LXRX Enterprise Value performed in the past?

The current Enterprise Value of Lexicon Pharmaceuticals, Inc. (LXRX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Lexicon Pharmaceuticals, Inc. (LXRX) Enterprise Value vs. Peers

How is LXRX’s Enterprise Value compared to its peers?

Lexicon Pharmaceuticals, Inc.’s Enterprise Value is less than Omeros Corporation (883.69M), greater than Bicycle Therapeutics plc (-152624053.00), greater than RAPT Therapeutics, Inc. (534.71M), greater than Fulcrum Therapeutics, Inc. (433.95M), less than Gossamer Bio, Inc. (930.39M), greater than 4D Molecular Therapeutics, Inc. (496.31M), greater than ADC Therapeutics S.A. (262.56M), greater than Neumora Therapeutics, Inc. Common Stock (251.41M), greater than Ocugen, Inc. (393.09M), less than Compass Therapeutics, Inc. (719.89M),

Build a custom stock screener for Lexicon Pharmaceuticals, Inc. (LXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexicon Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lexicon Pharmaceuticals, Inc. (LXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lexicon Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.